Antibody based immunotherapy for multiple myeloma: it's about time

Area of Science:

• Oncology
• Immunotherapy
• Hematology

Background:

• Monoclonal antibodies have significantly advanced cancer treatment.
• Multiple myeloma (MM) has historically seen limited benefit from this therapy.
• Recent advancements show a surge in therapeutic antibodies for MM.

Purpose of the Study:

• To review the current and emerging role of monoclonal antibodies in multiple myeloma treatment.
• To highlight key antibody therapies in development for MM.

Main Methods:

• Review of recent clinical development stages for monoclonal antibodies in MM.
• Analysis of therapeutic antibody targets such as CD38 and SLAMF7.
• Evaluation of early-stage immunotoxin development.

Main Results:

• Unconjugated anti-CD38 antibody Daratumumab and anti-SLAMF7 antibody elotuzumab are in advanced development.
• These antibodies are anticipated to significantly impact MM management.
• Early-stage immunotoxin Indatuximab Ravtansine shows encouraging results.

Conclusions:

• Monoclonal antibodies are increasingly vital in managing multiple myeloma.
• Their role is expected to expand, particularly in combination therapies.
• Combination strategies with other anti-myeloma agents are likely key for optimal outcomes.